Acute cerebellar dysfunction with high-dose ARA-C therapy

Martin Salinsky, R. L. Levine, J. P. Aubuchon, H. S. Schutta

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The authors report a patient with clinical and morphologic evidence of acute cerebellar toxicity after receiving high-dose cytosine arabinoside (ARA-C) (3000 mg/m2/12 hours) for refractory AML. Damage of Purkinje cells and dentate nucleus was demonstrated. Reversible cerebellar toxicity has previously been noted in patients on an identical regimen. Signs of cerebellar dysfunction mandate immediate cessation of high-dose ARA-C therapy.

Original languageEnglish (US)
Pages (from-to)426-429
Number of pages4
JournalCancer
Volume51
Issue number3
StatePublished - 1983
Externally publishedYes

Fingerprint

Cerebellar Diseases
Cerebellar Nuclei
Purkinje Cells
Cytarabine
Cell Nucleus
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Salinsky, M., Levine, R. L., Aubuchon, J. P., & Schutta, H. S. (1983). Acute cerebellar dysfunction with high-dose ARA-C therapy. Cancer, 51(3), 426-429.

Acute cerebellar dysfunction with high-dose ARA-C therapy. / Salinsky, Martin; Levine, R. L.; Aubuchon, J. P.; Schutta, H. S.

In: Cancer, Vol. 51, No. 3, 1983, p. 426-429.

Research output: Contribution to journalArticle

Salinsky, M, Levine, RL, Aubuchon, JP & Schutta, HS 1983, 'Acute cerebellar dysfunction with high-dose ARA-C therapy', Cancer, vol. 51, no. 3, pp. 426-429.
Salinsky M, Levine RL, Aubuchon JP, Schutta HS. Acute cerebellar dysfunction with high-dose ARA-C therapy. Cancer. 1983;51(3):426-429.
Salinsky, Martin ; Levine, R. L. ; Aubuchon, J. P. ; Schutta, H. S. / Acute cerebellar dysfunction with high-dose ARA-C therapy. In: Cancer. 1983 ; Vol. 51, No. 3. pp. 426-429.
@article{e4d2717415854eae93756f3caf38dbe4,
title = "Acute cerebellar dysfunction with high-dose ARA-C therapy",
abstract = "The authors report a patient with clinical and morphologic evidence of acute cerebellar toxicity after receiving high-dose cytosine arabinoside (ARA-C) (3000 mg/m2/12 hours) for refractory AML. Damage of Purkinje cells and dentate nucleus was demonstrated. Reversible cerebellar toxicity has previously been noted in patients on an identical regimen. Signs of cerebellar dysfunction mandate immediate cessation of high-dose ARA-C therapy.",
author = "Martin Salinsky and Levine, {R. L.} and Aubuchon, {J. P.} and Schutta, {H. S.}",
year = "1983",
language = "English (US)",
volume = "51",
pages = "426--429",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Acute cerebellar dysfunction with high-dose ARA-C therapy

AU - Salinsky, Martin

AU - Levine, R. L.

AU - Aubuchon, J. P.

AU - Schutta, H. S.

PY - 1983

Y1 - 1983

N2 - The authors report a patient with clinical and morphologic evidence of acute cerebellar toxicity after receiving high-dose cytosine arabinoside (ARA-C) (3000 mg/m2/12 hours) for refractory AML. Damage of Purkinje cells and dentate nucleus was demonstrated. Reversible cerebellar toxicity has previously been noted in patients on an identical regimen. Signs of cerebellar dysfunction mandate immediate cessation of high-dose ARA-C therapy.

AB - The authors report a patient with clinical and morphologic evidence of acute cerebellar toxicity after receiving high-dose cytosine arabinoside (ARA-C) (3000 mg/m2/12 hours) for refractory AML. Damage of Purkinje cells and dentate nucleus was demonstrated. Reversible cerebellar toxicity has previously been noted in patients on an identical regimen. Signs of cerebellar dysfunction mandate immediate cessation of high-dose ARA-C therapy.

UR - http://www.scopus.com/inward/record.url?scp=0020655750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020655750&partnerID=8YFLogxK

M3 - Article

C2 - 6571798

AN - SCOPUS:0020655750

VL - 51

SP - 426

EP - 429

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -